Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0005 EUR | -.--% | -.--% | -.--% |
06-17 | Neovacs: collaboration agreement with CNRS | CF |
06-10 | Neovacs: presents results from vaccine candidates | CF |
Business Summary
Sales per Business
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Immunotherapy
100.0
%
| 0 | 100.0 % | 1 | 100.0 % | +47,868.71% |
Sales per region
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
France
100.0
%
| 0 | 100.0 % | 1 | 100.0 % | +47,868.71% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Hugo Brugière
CEO | Chief Executive Officer | - | - |
Director of Finance/CFO | - | 20-09-30 | |
Vincent Serra
COO | Chief Operating Officer | 55 | 19-02-19 |
Charlène Masson
IRC | Investor Relations Contact | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 85 | 03-05-27 | |
Daniel Zagury
FOU | Founder | - | 93-04-15 |
Hugo Brugière
CEO | Chief Executive Officer | - | - |
Baudouin Hallo
BRD | Director/Board Member | - | - |
Muriel Haim
BRD | Director/Board Member | - | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 140 | 0 ( 0.1248 %) | 0 | 0.1248 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+23.13% | 52.73B | |
+37.49% | 39B | |
-8.73% | 38.52B | |
+28.09% | 30.38B | |
-12.26% | 26.39B | |
+10.57% | 26.08B | |
+45.05% | 14.15B | |
+32.23% | 12.6B | |
-6.56% | 11.51B |
- Stock Market
- Equities
- ALNEV Stock
- 0LW Stock
- Company NEOVACS SA